Abingdon, United Kingdom

Laura Gleave

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 13.9

ph-index = 2

Forward Citations = 7(Granted Patents)


Location History:

  • Oxon, GB (2014)
  • Abingdon, GB (2016 - 2024)

Company Filing History:


Years Active: 2014-2024

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Laura Gleave: Pioneering Innovator in PAD4 Inhibitor Development

Introduction

Laura Gleave is an accomplished inventor based in Abingdon, Great Britain, with a notable portfolio of six patents. Her work primarily focuses on innovative compounds that serve as inhibitors of PAD4, which play a crucial role in treating various PAD4-related disorders.

Latest Patents

Among her latest patents, Gleave's inventions, titled "Heteroaryl inhibitors of PAD4," detail compounds that demonstrate efficacy in inhibiting PAD4. The patents cover not only the compounds themselves but also compositions that can be derived from them, along with methodologies for treating disorders associated with PAD4. This groundbreaking work holds significant promise for advancing treatment options in the medical field.

Career Highlights

Laura Gleave has built a distinguished career at prominent organizations focused on biopharmaceutical advancements. She has worked at Padlock Therapeutics, Inc. and UCB Biopharma S.A., contributing her expertise in medicinal chemistry and pharmacology. Her dedication to innovative research has led to substantial developments in the understanding and application of PAD4 inhibitors.

Collaborations

In her journey as an inventor, Gleave has collaborated with talented professionals in her field. Notable colleagues include Rajesh Devraj and Gnanasambandam Kumaravel, who have contributed to the development and refinement of her innovative compounds. These collaborations highlight the importance of teamwork and shared expertise in driving forward advancements in science and medicine.

Conclusion

Laura Gleave's contributions through her patented inventions are paving the way for new therapeutic strategies targeting PAD4-related disorders. With her innovative spirit and collaborative efforts, she continues to make significant strides in the field of biopharmaceuticals, showcasing the transformative power of dedicated inventors in advancing healthcare technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…